Iofolastat I-123
DRACPC ID DRACPC0080
Active Ingredients Iofolastat I-123
Description An iodine 123-radiolabeled small molecule that exhibits high affinity for prostate-specific membrane antigen (PSMA) with potential use in molecular imaging. Iofolastat I123, a radiolabeled glutamate-urea-lysine analogue, selectively binds PSMA, which allows imaging of PSMA-expressing prostate cancer cells with gamma scintigraph. PSMA is a transmembrane glycoprotein highly expressed by malignant prostate epithelial cells and vascular endothelial cells of various solid tumors.
Synonyms 123-I-MIP-1072; Iodine I 123 MIP-1072; Iofolastat I123; L-Glutamic Acid, N-((((1S)-1-carboxy-5-(((4-(iodo-123i)phenyl)methyl)amino)pentyl)amino)carbonyl)-; N-(((1S)-1-carboxy-5-(((4-((Sup 123)i)iodophenyl)methyl)amino)pentyl)carbamoyl)-L-glutamic Acid
Type Small Molecule
Disease Prostate Cancer
Classification
Amino acid and derivative Radiopharmaceuticals
Structure Information
Molecular Formula C19H26IN3O7
Molecular Weight 531.3
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2S)-2-[[(1S)-1-carboxy-5-[(4-(123I)iodanylphenyl)methylamino]pentyl]carbamoylamino]pentanedioic acid
InChI InChI=1S/C19H26IN3O7/c20-13-6-4-12(5-7-13)11-21-10-2-1-3-14(17(26)27)22-19(30)23-15(18(28)29)8-9-16(24)25/h4-7,14-15,21H,1-3,8-11H2,(H,24,25)(H,26,27)(H,28,29)(H2,22,23,30)/t14-,15-/m0/s1/i20-4
InChI_Key OXUUJYOSVPMNKP-ZANJDRPYSA-N
SMILES O=C(CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNCC1=CC=C(C=C1)[123I])=O)O
External Codes
PubChem CID 25194767
DrugBank Accession Number DB12514
NCI Thesaurus Code Not available
UNII AQF0A29T2V GSRS
CAS 949575-24-0
Drug approval
Drug indication
Investigated for use/treatment in Prostate Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00712829 | A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen: Determination of I-123 Radiation Dosimetry for 123-I-MIP-1072 and 123-I-MIP-1095 | Prostate Cancer | Phase 1 | Diagnostic |
More clinical information is obtained from ClinicalTrials.gov.
